380 related articles for article (PubMed ID: 17139378)
1. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
2. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin.
Amirkhosravi A; Mousa SA; Amaya M; Francis JL
J Thromb Haemost; 2003 Sep; 1(9):1972-6. PubMed ID: 12941039
[TBL] [Abstract][Full Text] [Related]
3. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor.
Bara L; Bloch MF; Zitoun D; Samama M; Collignon F; Frydman A; Uzan A; Bouthier J
Thromb Res; 1993 Mar; 69(5):443-52. PubMed ID: 8388583
[TBL] [Abstract][Full Text] [Related]
5. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
Schick BP; Maslow D; Moshinski A; San Antonio JD
Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
[TBL] [Abstract][Full Text] [Related]
6. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma.
Amirkhosravi A; Meyer T; Chang JY; Amaya M; Siddiqui F; Desai H; Francis JL
Thromb Haemost; 2002 Jun; 87(6):930-6. PubMed ID: 12083498
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
8. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
9. Preparation and evaluation a new generation of low molecular weight heparin.
Zhao D; Sang Q; Cui H
Biomed Pharmacother; 2016 Apr; 79():194-200. PubMed ID: 27044828
[TBL] [Abstract][Full Text] [Related]
10. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands.
Rao NV; Argyle B; Xu X; Reynolds PR; Walenga JM; Prechel M; Prestwich GD; MacArthur RB; Walters BB; Hoidal JR; Kennedy TP
Am J Physiol Cell Physiol; 2010 Jul; 299(1):C97-110. PubMed ID: 20375277
[TBL] [Abstract][Full Text] [Related]
11. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis.
Gonzalez-Fajardo JA; Arreba E; Castrodeza J; Perez JL; Fernandez L; Agundez I; Mateo AM; Carrera S; Gutiérrez V; Vaquero C
J Vasc Surg; 1999 Aug; 30(2):283-92. PubMed ID: 10436448
[TBL] [Abstract][Full Text] [Related]
12. Effect of unfractionated heparin and low molecular weight heparin on the clotting of platelet-reduced whole blood: an in-vitro study utilizing thromboelastography.
Chung J; Stevic I; Gantioqui J; Atkinson H; Chan AKC; Chan HHW
Blood Coagul Fibrinolysis; 2021 Jul; 32(5):305-311. PubMed ID: 34231501
[TBL] [Abstract][Full Text] [Related]
13. Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice.
Rossi C; Hess S; Eckl RW; di Lena A; Bruno A; Thomas O; Poggi A
J Thromb Haemost; 2006 Mar; 4(3):608-13. PubMed ID: 16460443
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action.
Hansen JB; Sandset PM; Huseby KR; Huseby NE; Bendz B; Ostergaard P; Nordøy A
Br J Haematol; 1998 Jun; 101(4):638-46. PubMed ID: 9674734
[TBL] [Abstract][Full Text] [Related]
15. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations.
Klein SM; Slaughter TF; Vail PT; Ginsberg B; El-Moalem HE; Alexander R; D'Ercole F; Greengrass RA; Perumal TT; Welsby I; Gan TJ
Anesth Analg; 2000 Nov; 91(5):1091-5. PubMed ID: 11049889
[TBL] [Abstract][Full Text] [Related]
16. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant effects of low-molecular-weight heparins in healthy cats.
Alwood AJ; Downend AB; Brooks MB; Slensky KA; Fox JA; Simpson SA; Waddell LS; Baumgardner JE; Otto CM
J Vet Intern Med; 2007; 21(3):378-87. PubMed ID: 17552440
[TBL] [Abstract][Full Text] [Related]
18. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
Brophy DF; Martin EJ; Gehr TW; Carr ME
Am J Kidney Dis; 2004 Aug; 44(2):270-7. PubMed ID: 15264185
[TBL] [Abstract][Full Text] [Related]
19. Thromboelastometry versus free-oscillation rheometry and enoxaparin versus tinzaparin: an in-vitro study comparing two viscoelastic haemostatic tests' dose-responses to two low molecular weight heparins at the time of withdrawing epidural catheters from ten patients after major surgery.
Thomas O; Larsson A; Tynngård N; Schött U
BMC Anesthesiol; 2015 Nov; 15():170. PubMed ID: 26603039
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide.
Poggi A; Rossi C; Casella N; Bruno C; Sturiale L; Dossi C; Naggi A
Semin Thromb Hemost; 2002 Aug; 28(4):383-92. PubMed ID: 12244486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
